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Abstract
Background: The emergence of drug resistant typhoid fever is a major public health problem, especially in Asia. An oral
single dose typhoid vaccine would have major advantages. M01ZH09 is a live oral single dose candidate typhoid vaccine
containing Salmonella enterica serovar Typhi (Ty2 aroC
2 ssaV
2) ZH9 with two independently attenuating deletions. Studies
in healthy adults demonstrated immunogenicity and an acceptable safety profile.
Objectives: We conducted a randomised placebo controlled, single-blind trial to evaluate the safety and immunogenicity of
M01ZH09 in healthy Vietnamese children aged 5 to 14 years.
Methods: Subjects were randomly assigned to receive either a nominal dose of 5610
9 CFU of M01ZH09 or placebo and
were followed up for 28 days. The primary safety outcome was the proportion of subjects with any adverse event attributed
to M01ZH09. The primary immunogenicity endpoint was the proportion of subjects who showed a positive immune
response to M01ZH09 in the Salmonella Typhi lipopolysaccharide (LPS) specific serum IgA and IgG ELISA.
Principal Findings: One hundred and fifty-one children were enrolled, 101 subjects received M01ZH09 and 50 subjects
received placebo. An intention to treat analysis was conducted. There were no serious adverse events and no bacteraemias.
In the M01ZH09 group, 26 (26%; 95% CI, 18–5%) of 101 subjects experienced adverse events compared to 11 (22%; 95% CI,
12–36%) of 50 subjects in the placebo group (odds ratio (OR) [95%CI] =1.23 [0.550–2.747]; p=0.691). Faecal shedding of S.
Typhi (Ty2 aroC
2 ssaV
2) ZH9 was detected in 51 (51%; 95% CI, 41–61%) of 100 M01ZH09 subjects. No shedding was
detected beyond day 3. A positive immune response, defined as 70% increase (1.7 fold change) in LPS specific serum IgG
(day 14 or 28) and/or 50% increase (1.5 fold change) in LPS specific serum IgA (day 7 or 14) from baseline was detected in 98
(97%; 95% CI, 92–99%) of 101 M01ZH09 recipients and 8 (16%; 95% CI, 7–29%) of 50 placebo recipients. Twenty-eight
(100%; 95% CI, 88–100%) of 28 vaccine recipients who were evaluated in the LPS specific IgA ELISPOT assay showed a
positive response compared to none of the 14 placebo recipients tested.
Conclusions: This was the first phase II trial of a novel oral candidate typhoid vaccine in children in an endemic country.
M01ZH09 had an appropriate safety profile and was immunogenic in children.
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Introduction
Typhoid fever remains a major public health burden in
developing countries with approximately 21 million cases and
more than 210 000 deaths worldwide per year [1].
Drug resistant typhoid fever has emerged and spread globally
narrowing the treatment options [2–4]. The World Health
Organization therefore recommends that countries should con-
sider the programmatic use of typhoid vaccines for controlling
endemic diseases and that the immunization of school age and/or
preschool age children should be undertaken particularly in areas
where antibiotic resistant Salmonella enterica serovar Typhi (S.
Typhi) is prevalent [5].
Two licensed and safe typhoid vaccines are available. The oral
live attenuated Ty21a vaccine is moderately immunogenic and
needs to be administered in three to four doses. Ty21a enteric-
coated capsules and Ty21a liquid formulation (which is currently
not manufactured) are licensed for children above 6 years and 2
years, respectively. The single dose injectable Vi polysaccharide
vaccine is licensed for children above 2 years. The liquid
formulation of Ty21a and Vi vaccine provide about 55 to 70%
protection from culture confirmed typhoid fever and protection
lasts for 3 to 5 years [5,6].
From a public health perspective, a single dose oral typhoid
vaccine would have major advantages [7,8]. M01ZH09 (S. Typhi
(Ty2 aroC
2 ssaV
2) ZH9) is a promising candidate of such a novel
typhoid vaccine, it has a well-defined dual mechanism of
attenuation [9] and has been safe and immunogenic in a single
dose in Western [9–11] and Vietnamese adult volunteers (Hien
TT, unpublished).
Historically, oral live vaccines often showed reduced immuno-
genicity in developing country populations compared to Western
populations [12], therefore M01ZH09 was evaluated at an early
stage of its development in children in an endemic country.
We describe here the results of a randomised placebo controlled
trial that evaluated the safety and immunogenicity of M01ZH09 in
151 healthy Vietnamese children aged between 5 and 14 years.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information, see Protocol S1 and
Checklist S1.
Study design and objectives
The study was designed as a randomised placebo controlled
single blind trial to evaluate the safety and immunogenicity of the
novel oral single dose live typhoid vaccine M01ZH09 in
Vietnamese children aged 5 to 14 years (inclusive).
The study site and ethical approval
The trial was conducted at the Hospital for Tropical Diseases in
Ho Chi Minh City, Vietnam. Ethics approval for the trial and all
trial related documents was obtained by the Oxford Tropical
Research Ethics Committee (OXTREC) and by the Institutional
Review Board of the Ministry of Health, Hanoi, Vietnam. The
trial was conducted in accordance with the Declaration of Helsinki
and its amendments and according to Good Clinical Practice
guidelines and was monitored by Matrix Contract Research Ltd.,
UK (now Novella Clinical). The trial was also conducted under an
US Investigational New Drug (IND) license.
Participants
Healthy Vietnamese children aged 5 to 14 years (inclusive) were
invited to participate in the trial. Recruitment was carried out by
word of mouth and flyers. Families who were interested in the trial
were invited to attend one of several information evenings at the
Hospital for Tropical Diseases. At these meetings the study was
presented by the principal investigator (TTH) and all questions
could be discussed and answered. Families who remained
interested in the trial were invited to attend the screening visit.
Children were eligible if they were available during the trial period
and at least one of their parents gave written informed consent for
their child to participate after the trial procedures and potential
risks were carefully explained by the study investigators. All
children were invited to give their assent to the study and written
informed assent was obtained from subjects starting at the age of 6
years. After informed consent was obtained, screening tests were
performed. Children were screened by history, physical examina-
tion (including height, weight and vital signs), blood tests
(biochemistry, haematology and HIV test), urine dipsticks and
pregnancy tests (for female subjects of 11 years and above). Stool
cultures were performed to check for the presence of Salmonella
species.
Subjects with a history of typhoid fever, Ty21a vaccination in
the last 10 years or any other typhoid vaccine in the last 5 years,
any clinically significant illness, abnormal blood test results,
immune suppression, positive HIV or pregnancy test were
excluded. Also excluded were subjects whose body weight was
under 17 kg in the 5 to 10 year old group or under 27 kg in the 11
to 14 year old group and subjects who suffered from an acute
febrile illness at the time of dosing (the complete list of exclusion
criteria is available in the trial protocol). Only one child per family
was allowed to participate in the trial.
The results of the screening tests were reviewed and subjects
who continued to meet the inclusion criteria were invited to
continue in the trial.
The M01ZH09 vaccine and dose
S. Typhi (Ty2 aroC
2 ssaV
2) ZH9 was constructed with a rational
attenuation strategy. Two defined independently attenuating
deletion mutations were introduced into S. Typhi Ty2. Deletion
of aroC, encoding chorismate synthase, prevents the biosynthesis of
aromatic amino acids and deprives the live vaccine bacterium of
essential nutrients. Deletion of ssaV, encoding a structural
component of the Salmonella pathogenicity island-2 (SPI-2) type
III secretion system, prevents systemic spread of S. Typhi [9]. The
vaccine was manufactured according to Good Manufacturing
Practice protocols by Eurogentec S.A. and SynCo Bio Partners
B.V; batch number M-STZH9-F16 was shipped to Vietnam. The
vaccine kits were stored at 2–8uC
Previous studies in adult volunteers demonstrated that a
nominal dose of 5610
9 CFU of the vaccine strain was immuno-
genic and safe [9–11]. The Ty21a oral typhoid vaccine capsules
are licensed for adults and children above 6 years using the same
dose and immunization schedule and large Ty21a field trials in
children used the same dose and regimen as in adults [13]. It was
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study was a nominal dose of 5610
9 CFU of S. Typhi (Ty2 aroC
2
ssaV
2) ZH9.
The vaccine (containing 5610
9 CFU of vaccine strain plus
excipients) and the placebo (vaccine excipients only) were supplied
as freeze-dried formulations in single dose vials, which were
labeled identically, containing ‘‘M01ZH09 oral typhoid vaccine or
placebo’’ but with a unique subject number corresponding to the
randomisation list. The bicarbonate solution was prepared by
dissolving one effervescent bicarbonate tablet (provided in the
vaccine kit and containing 2.6 g sodium bicarbonate, 1.65 g
ascorbic acid and 30 mg aspartame) in 150 ml of bottled drinking
water (final concentration: 1.75% wt/vol sodium bicarbonate,
1.1% wt/vol ascorbic acid, and 0.02% wt/vol aspartame). The
lyophilised vaccine or placebo was reconstituted in either 150 ml
(for children above 10 years) or in 75 ml of the bicarbonate
solution (the other 75 ml were discarded) for children below 10
years and was administered immediately.
The study used two age group specific randomisation lists, one
for the 11 to 14 year old and one for the 5 to 10 year old children
to ensure at least 70% children were between 5 to 10 years old.
Intervention
On the day of vaccination (day 0) which took place within 28
days of the screening, inclusion and exclusion (including history of
antibiotic medication in the last 2 weeks) criteria were reviewed.
Pregnancy tests (female subjects of 11 years and above only), urine
dipstick test and stool cultures were performed. Blood samples for
haematology, biochemistry, ELISA and ELISPOT assays (only in
children 11 years and above) were obtained. After the subjects had
fasted for at least 2 hours (with the exception of drinking water),
the candidate typhoid vaccine or placebo was administered.
Subjects were allocated the next age-group specific subject
number and the medication pack bearing the same number was
prepared and issued by the pharmacist, who was otherwise not
involved in the trial. The subjects were randomly assigned to
receive either M01ZH09, consisting of 5610
9 CFU of S. Typhi
(Ty2 aroC
2 ssaV
2) ZH9 or the placebo reconstituted in
bicarbonate solution as described above.
Volunteers were observed for at least 90 minutes at the hospital.
During this time pulse and blood pressure were recorded
periodically and only drinking water was provided.
Diary cards were issued for all the volunteers and all subjects
received a basic hygiene kit containing soap, gloves and spatulas
for the collection of stool samples. The subjects and their parents
were instructed to measure and record the oral temperature of the
children twice daily (morning and evening) and to record any
adverse events (including headache, fever, nausea, vomiting,
abdominal pain, frequency and consistency of stools and any
other symptoms) for 14 days.
Follow up procedures and monitoring of adverse events
Children were followed up daily from days 1 to 14 and again on
day 28 after dosing. At these appointments diary cards were
checked and adverse events and concomitant medication
reviewed. A history of the last 24 hours with special emphasis on
temperatures of 38.5uC and above and adverse events (diarrhoea,
loss of appetite, vomiting, headache and chills) was obtained. Oral
temperatures and vital signs were recorded and children were
examined for signs of splenomegaly. Stool cultures were performed
daily from day 1 to day 14. Blood samples for biochemistry and
haematology were obtained on days 7, 14 and 28; for the LPS
specific serum IgA ELISA on days 7 and 14; for the IgG ELISA on
days 14 and 28 and for the LPS specific IgA antibody secreting cell
(ASC) ELISPOT assay (only in subjects aged 11 years and above)
on day 7. The total amount of blood taken during this study was
approximately 28 ml from the 5 to 10 years old and 44 ml from
the 11 to 14 years old children.
Unscheduled visits
Subjects and parents were instructed to make additional visits to
the clinic, if the child felt unwell and/or had a fever of $38.5uC.
At these visits the subject was assessed and samples taken for
culture as clinically indicated. Blood cultures to investigate for the
presence of S. Typhi in blood would be obtained if a fever of
$39.0uC was recorded twice over a 48 hours period, or a severe
fever of $39.5uC was recorded once.
Definition and reporting of serious adverse events and
definition of stopping rules
There was no Data Safety and Monitoring Committee for this
trial. Data from all children were reviewed daily and there were a
priori defined stopping rules which would trigger a suspension of
the trial and a safety review (Protocol S1). Serious adverse events
were reported to AKOS Ltd (Hitchin, UK), a pharmacovigilance
company within 24 hours.
Detection of Salmonella in stool samples at the screening
visit and day 0
The detection of Salmonella species at the screening visit and on
day 0 was performed according to microbiological standard
procedures. In brief, stool samples were inoculated onto
MacConkey agar and xylose lysine deoxycholate (XLD) agar
plates, and in 10 ml of selenite F broth. Plates and broth were
incubated at 37uC overnight and the broth was sub-cultured on
MacConkey and XLD agar plates the next morning. Isolates were
screened using standard biochemical tests and Salmonella were
identified by slide agglutination with specific antisera (Oxoid Ltd.,
UK) and API20E profiling (bioMe ´rieux, UK).
Detection of S. Typhi in stool samples
Stool samples were collected daily between days 1 and 14. Stool
samples were cultured directly on deoxycholate citrate agar (DCA)
Hynes plates (direct method) and in selenite F broth (enriched
method), both of which were supplemented with aromatic
compounds (DCA-aro and selenite F-aro, respectively) to detect
S. Typhi, including the auxotrophic vaccine strain, in stools.
Following overnight incubation at 37uC, an aliquot of the
inoculated selenite F-aro broth was sub-cultured on DCA-aro
Hynes plates. Suspected S. Typhi colonies were inoculated on
brain heart infusion agar plates supplemented with aromatic
compounds (BHI-aro). Oxidase negative colonies were evaluated
by agglutination with Hd, Vi and O9 anti-sera (Oxoid Ltd., UK)
and API20E profiling (bioMe ´rieux, UK). Stool samples containing
isolates that were positive in at least 2 out of 3 agglutinations and
identified as S. Typhi by API20E profiling were considered to be
positive for S. Typhi. All isolates were stored in 10% (v/v) glycerol
at 280uC.
Detection of S. Typhi in blood samples
Blood samples were collected into either Bactec Peds Plus/F
culture bottles (1–3 ml blood; BD, USA) or Bactec Plus Aerobic/F
culture bottles (4–10 ml blood; BD, USA) and supplemented with
aromatic compounds. Blood cultures were incubated at 35uCi n
the Bactec detection system and monitored for up to 5 days. Gram
stain was performed on all bottles triggering a positive reaction.
Positive cultures and all cultures that were negative after 5 days of
M01ZH09 Vaccine in Children
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Typhi colonies were sub-cultured onto BHI-aro agar plates.
Oxidase negative isolates were evaluated by agglutination and
API20E profiling (bioMe ´rieux, UK) as above.
PCR identification of S. Typhi isolates
Genomic DNA was isolated from glycerol stocks of S. Typhi
isolates using a DNeasy blood and tissue kit (Qiagen, UK).
Multiplex PCRs were performed using a Taq PCR core kit
(Qiagen, UK). Each reaction mixture contained 200 mM dNTPs,
0.4 mM ssaV4 (59 ATCCCCACGACTTCAGCAAG 39) and
ssaV7 (59 CTTTCTGGCTCATCATGAGG 39), and 0.1 mM
aroC.Z1 (59 GACAACTCTTTCGCGTAACC 39) and aroC.Z3
(59 TTACATCCGCATTCTGTGCC 39), 10 ng genomic DNA
and 1.25 u Taq DNA polymerase in a total volume of 50 ml
reaction buffer. PCRs were performed for 25 cycles as follows:
94uC for 30 sec, 57uC for 30 sec and 72uC for 2.5 min. The PCR
products were visualised by ethidium bromide staining and UV
transillumination after electrophoresis on a 0.8% (w/v) TAE
agarose gel. The expected sizes of the PCR products were 1.04 kb
(aroC) and 2.59 kb (ssaV) for S. Typhi wild-type strains and 0.45 kb
(aroC) and 0.70 kb (ssaV) for S. Typhi (Ty2 aroC
2 ssaV
2) ZH9.
Detection of antibody secreting cells producing S. Typhi
LPS specific IgA antibodies by ELISPOT assay
ELISPOT assays to detect antibody secreting cells (ACS)
producing S. Typhi LPS specific IgA antibodies were performed
on days 0 and 7 as described previously [10,14]. In brief, whole
blood was collected in heparinised cell preparation tubes
(Vacutainer CPT; BD, UK) and centrifuged. Peripheral blood
mononuclear cells (PBMCs) were washed, resuspended in culture
medium and adjusted to three cell concentrations (1610
7/ml,
5610
6/ml and 2.5610
6/ml). One hundred microlitres of each
concentration were added to LPS coated and uncoated wells (for
subtraction of non-specific results) of nitrocellulose microtiter
plates (Millipore, USA) and incubated overnight at 37uCi na5 %
CO2 incubator. PBMC collected from a healthy volunteer who
had received three doses of Ty21a (Vivotif, Berna, Switzerland)
were included as positive control and PBMC from a non-
vaccinated person as negative control. Plates were washed and an
alkaline phosphatase-conjugated anti-human IgA antibody (Im-
mune Systems Ltd., UK) was added and incubated for one hour.
Plates were washed and spots were visualised by the addition
of 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium
(BCIP/NBT) substrate. Antibody secreting cell (ASC) spots were
counted manually using an inverted microscope. If more than 100
spots per well were present, the result was described as ‘‘too many
spots to be counted’’. A positive response in the ELISPOT assay
on day 7 was defined as $4 IgA ASC specific for LPS per 10
6
PBMCs and a negative response as ,4 IgA ASC specific for LPS
per 10
6 PBMCs. Subjects with a day 0 result of $4 ASC per 10
6
PBMC were excluded from the ELISPOT analysis. ELISPOT
assays were performed at the Hospital for Tropical Diseases.
Analysis of S. Typhi LPS specific serum IgG and IgA by
ELISA and definition of a positive immune response
Quantitative ELISA methods for measuring S. Typhi LPS
specific serum IgG and IgA were developed and qualified by
Emergent Product Development UK Ltd using serum samples
from recipients of M01ZH09 who participated in prior clinical
trials and who had given informed consent for retention and usage
of their samples. For the IgG ELISA, serum which demonstrated
more than 4-fold increase from pre-dose in a previously described
end point titre assay [11] were pooled and used as reference
standard. The LPS specific IgG concentration in the standard
serum was set arbitrarily at 30000 units/ml. For the IgA ELISA,
serum from past recipients of M01ZH09 who demonstrated
positive response in IgA ELISPOT were pooled and used as
reference standard. The LPS specific IgA concentration in the
standard serum was set arbitrarily at 100 units/ml.
Precision was evaluated as part of the assay qualification
exercise. Variance component analysis was carried out (PRISM
Training & Consultancy Ltd, UK) to calculate the standard error
of measured sample means and the least significant difference
(LSD) between two samples at the 1% significance level; this was
used as the cut-off value for a positive result in the respective assay.
A positive serum IgG response was defined as a 70% increase (fold
change of 1.7) as compared to the corresponding baseline sample,
whereas a positive serum IgA response was defined as a 50%
increase (fold change of 1.5) as compared to baseline.
Serum samples for measurement were frozen at 220uC and
shipped to Emergent Product Development UK Ltd for the
ELISA analyses. For the IgG ELISA, microtiter plates were coated
with S. Typhi LPS, washed and then blocked. Washing occurred
between each step. Calibration standards and diluted test samples
were added, and the plates were incubated. Bound IgG was
detected using an anti-human IgG antibody conjugated to
horseradish peroxidise (HRP) (Dako, Denmark) followed by the
addition of 3,39,5,59-Tetramethylbenzidine (TMB) substrate. The
plates were read at 450 nm within 30 minutes of stopping the
reactions with 0.3 mol/L sulphuric acid. The standard curve was
constructed by plotting the optical densities (ODs) of standards
against concentrations and fitted by a 4-parameter logistic
equation (SoftMaxH Pro 4.6, Molecular Devices, USA). The
concentration of LPS specific IgG in each sample was determined
from the standard curve. The IgA quantitative ELISA was
performed in a similar manner, except using a double detection
system of biotinylated anti-human IgA antibody (Southern
Biotech, USA) followed by streptavidin-HRP conjugate (Dako,
Denmark).
Outcomes of the study
Safety Outcomes. The primary safety endpoint was the
proportion of subjects with any adverse events attributed to
M01ZH09. The secondary safety endpoint was the proportion of
subjects with any serious related adverse events; any related or
unrelated adverse events; persisting faecal shedding of S. Typhi
(Ty2 aroC
2 ssaV
2) ZH9 after day 7; and/or had a fever of 38.5uC
or greater in the 14 days post vaccination, withdrew from the trial
due to adverse events, including bacteraemia, and/or had
clinically significant changes in laboratory parameters related to
the candidate vaccine.
All subjects who received a dose of the vaccine or placebo were
analysed in the safety population. Post-vaccination adverse events
were categorised according to body system and preferred term
using the Medical Dictionary for Regulatory Activities (MedDRA,
Version 9.1), allocated before unblinding. Adverse events were
graded by severity (mild, moderate, severe) and judged for the
relatedness to the study vaccine (unlikely, possibly, probably) by
the investigator. Only possibly and probably related adverse events
were attributed to the vaccine. Moderate fever was defined as an
oral temperature of $38.5uC and severe fever as an oral
temperature of $39.5uC. Moderate diarrhoea was defined as
more than 4 unformed stools and severe diarrhoea as more than 6
unformed stools in a 24 hour period or evidence of significant
dehydration. All adverse events were recorded in the CRFs and
monitored until return to normal.
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events were listed by body system. A per subject analysis of adverse
events was performed e.g., if a subject reported the same adverse
event on three occasions that adverse event was only counted
once. Subjects reporting more than one adverse event per body
system were counted only once in that body system total.
Immunogenicity Outcomes. The primary immunogenicity
endpoint was the proportion of subjects who developed a positive
immune response to S. Typhi LPS defined by an increase of 70%
(1.7 fold change) in LPS specific serum IgG on day 14 or 28 and/
or an increase of 50% (1.5 fold change) in LPS specific serum IgA
on day 7 or 14 compared to baseline.
The secondary immunogenicity endpoints were defined as the
proportion of subjects who developed a positive immune response
in each of the following assessments: S. Typhi LPS specific IgA
ELISA assay on days 7 or 14, S. Typhi LPS specific IgG ELISA
assay on days 14 or 28 and S. Typhi LPS specific IgA ELISPOT
on day 7. A positive ELISPOT was defined as $4 IgA antibody
secreting cells specific for S. Typhi LPS per 10
6 PBMCs.
Sample Size
The planned sample size was 150 subjects, of whom at least
70% should be aged 10 years or younger, as this was the target age
of the vaccine, randomised to M01ZH09 or placebo in a 2:1 ratio.
No formal sample size calculation was considered appropriate;
it was aimed to include a sufficient sample size to assess safety and
immunogenicity based on previous observations in adult studies
and immunogenicity rates of licensed typhoid vaccines in
children.
Randomisation procedures and assignment of
intervention (sequence generation, allocation
concealment, implementation)
Randomisation codes were computer generated in blocks of 9
by Statwood Ltd, UK. The vaccine and the placebo were labeled
identically but with a unique subject number corresponding to
the randomisation list. The study used two age group specific
randomisation lists, one for the 11 to 14 year old and one for the 5
to 10 year old children to ensure at least 70% children were
between 5 to 10 years old.
Subjects were allocated the next age-group specific subject
number in strict numerical sequence from this list and the
medication pack bearing the same number was prepared by the
pharmacist.
Blinding
This study was formally a single blind study due to slight
differences in taste and aroma between the treatment preparations
but it was conducted under the principles of a double blind study.
M01ZH09 and placebo were packaged and labeled identically but
with a unique sequential number. Possible sources of unblinding
could have been the preparation of the vaccine, therefore the
study pharmacist was otherwise not involved in the trial. The
subjects were asked to not report the taste of the vaccine.
Microbiology results were not reviewed by the investigators for at
least 14 days after vaccination to avoid potential unblinding
through shedding in stools. Immunology results were not reviewed
by the investigators. The study site received code break envelopes
in case an emergency made unblinding for a single subject
necessary. No codes were broken during this study. The
unblinding of treatment allocations took place after the trial had
been completed and the whole database had been entered and
locked.
Data collection, data entry and statistical methods
All data were recorded in Case Record Forms (CRFs). CRFs
were reviewed and collected by the study monitor. Data entry,
data management and statistical analysis were conducted by
Statwood, UK using SASH software (version 9.1). Data were
double entered and analysed according to an a priori defined
statistical analysis plan which included the definition of all subject
populations and the trial endpoints. The safety population
included all subjects who received the study medication. The
intention to treat (ITT) population comprised all dosed subjects
who had any post-dose immunogenicity data available. The per
protocol (PP) population excluded major protocol violators (failure
to meet the inclusion/exclusion criteria, to comply with the study
medication or use of other vaccinations or antibiotics two weeks
before until 2 weeks after vaccination, or use of antacids or proton-
pump inhibitors prior to vaccination and/or did not provide
samples for the ELISAs). The protocol stated that a confirmatory
analysis of the primary immunogenicity endpoint in the PP
population was planned if more than 5% of subjects were
excluded.
The proportion of subjects who experienced post-dose adverse
events was presented together with their two-sided 95%
confidence intervals (95%CI). Post dose adverse events, adverse
events considered to be related to the vaccine and adverse events
that occurred in more than 10% of the trial population were tested
using a two-sided Fisher’s exact test to compare between the two
groups.
The proportion of subjects who developed a positive immune
response was presented together with their two-sided 95%
confidence intervals calculated by using an exact Binomial
distribution. The treatment difference and associated 95%
confidence interval were presented as above. All available data
from withdrawn subjects was included in the analysis.
Results
Participant flow and recruitment
The trial was conducted between April and July 2007. In total,
205 healthy Vietnamese children between 5 and 14 years
(inclusive) were screened for eligibility. Fifty-four children were
not eligible (Figure 1), the most common reasons were unavail-
ability for the whole study period (n=10) and a positive stool
culture for Salmonella species at screening (non-typhoid Salmonella,
n=22). No S. Typhi or S. Paratyphi A were detected in stools at
the screening visits.
One hundred and fifty-one children were randomised, 101
children received the candidate typhoid vaccine M01ZH09 and 50
children received placebo. All subjects fulfilled the inclusion and
exclusion criteria at screening and dosing, however two subjects
(both in the M01ZH09 group) had clinically significant elevated
white blood counts (16.3 and 18.2610
9/L respectively) on day 0,
these results were only available after dosing.
One subject in the M01ZH09 group vomited after taking
approximately 50% of the required vaccine dose. The subject
agreed to take another dose, but failed to retain it. Three subjects
withdrew from the study, one placebo recipient withdrew due to
non-compliance (refused to provide stool samples) after day 2 and
two vaccine recipients left the study after day 6 (one wished to
withdraw, the second subject went on holiday). All three subjects
attended the day 28 visit. The remaining subjects attended all
study visits. Two subjects had unscheduled visits. One subject in
the vaccine group attended the clinic on day 16 because of fever of
38.1uC and one subject in the placebo group returned on day 26
with a temperature of 38.0uC. Blood cultures were obtained from
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recipient had unscheduled tests performed. The subject presented
on day 10 with a temperature of 38.6uC and reported diarrhoea,
vomiting and fever on the previous day. The white blood count
was elevated with 14.2610
9/L and the blood culture result was
negative.
Numbers analysed
All 151 children who were randomised and received either
M01ZH09 (n=101) or placebo (n=50) constituted the intention
to treat (ITT) population. Seven subjects, 4 in the vaccine group
and 3 in the placebo group were protocol violators (see Fig. 1) and
were excluded from the per protocol (PP) population. The analysis
of the primary endpoints in the PP population was planned if more
than 5% of subjects were excluded from the ITT. The PP
population comprised 95% (144/151) of subjects and therefore no
per protocol analysis was conducted.
All outcomes were evaluated for the ITT population.
Baseline data
The two groups did not differ significantly at enrolment in
terms of sex, age and laboratory parameters (Table 1). One
hundred and seven (71%) children were aged 10 years or
younger.
Two subjects in the M01ZH09 group had clinically significant
elevated white blood counts on day 0 (see above). Twelve subjects
Figure 1. Flow of subjects.
doi:10.1371/journal.pone.0011778.g001
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group (this included the subject who vomited on the day of dosing)
had a positive stool culture for non-typhoid Salmonella on day 0,
these results were only available after dosing.
Protocol deviations and modifications
The protocol stated that the primary safety endpoint would be
the proportion of subjects reporting serious adverse events
attributed to M01ZH09. Due to concerns that these numbers
might be small and would not be sufficient to detect a difference in
safety between the two groups, the primary endpoint was changed
to the proportion of subjects with any related adverse event. This
change was made after the completion of the clinical phase but
prior to database lock and unblinding.
Outcomes and estimation
Safety Outcomes. There were no serious adverse events, no
bacteraemia and none of the subjects withdrew due to adverse
events in this trial.
Similar proportion of subjects reported adverse events in both
treatment groups during the 28 days of follow up, but the total
number of events was higher in the M01ZH09 group. In the
vaccine group, 26 (26%; 95%CI, 18–35%) of 101 subjects
reported 64 adverse events compared to 11 (22%; 95%CI,
12–36%) of 50 subjects in the placebo group who reported 17
adverse events (odds ratio (OR) [95%CI] =1.23 [0.55022.747];
p=0.691) (Table 2). Repeated occurrences of a particular adverse
event in the same subject were included in the total number of 64
and 17 adverse events, respectively. Of the 64 adverse events
reported by M01ZH09 recipients, 55 were mild (8 of these were
considered to be related to the candidate vaccine), 8 moderate (one
related) and one was severe and related to M01ZH09 (Table 2). Of
the 17 adverse events in the placebo group, 12 were mild, 5
moderate and none was related.
Four (4%) M01ZH09 recipients experienced 10 adverse events
that were related to the candidate vaccine compared to none in the
placebo group (p=0.302). Of these, 8 were mild, one moderate
(diarrhoea) and one event of pyrexia was severe. The moderate
and the severe related adverse events occurred in the same subject.
This subject had a normal temperature on day 0, but the pre-dose
blood test showed an elevated white blood cell count (16.3610
9/
L). The subject experienced five post vaccination adverse events
occurring on day 0, including fever of 38.5 and 39.0uC, diarrhoea,
headache, abdominal pain and anorexia. The subject received
paracetamol and recovered.
Similar proportions of subjects experienced fever post vaccina-
tion (Table 2), only one subject reported fever related to
M01ZH09 (see above).
Adverse events classified as gastrointestinal disorders, nervous
system disorders and investigations were experienced by a higher
proportion of M01ZH09 recipients (Table 2). Twelve (12%)
vaccine recipients experienced gastrointestinal disorders compared
to 1 (2%) placebo recipient (p=0.061). Nervous system disorders
(headache) occurred in 9 (9%) vaccine recipients compared to 1
(2%) placebo recipient (p=0.166) and investigations were reported
by 4 (4%) vaccine recipients compared to none of the placebo
recipients (p=0.302).
Cough was the most frequently reported adverse event,
occurring in 6 (6%) M01ZH09 recipients versus 7 (14%) placebo
recipients (p=0.124).
On day 1 after vaccination, faecal shedding of S. Typhi
occurred in 47 (49%) of 95 vaccine recipients; shedding was
detected by the direct method in 11 (12%) subjects and by the
enriched method of culturing stools in 36 (38%) subjects. On day 2
after vaccination, faecal shedding was detected in 12 (12%) of 97
subjects (in 1 (1%) subject by direct and in 11 (11%) subjects by
enriched method). Only one (1%) of 98 subjects experienced
shedding on Day 3 (detected by enrichment method). In total, 51
(51%; 95% CI, 41–61%) of 100 M01ZH09 subjects experienced
Table 1. Baseline characteristics of the subjects on day 0 (Intention to Treat population).
Characteristics M01ZH09 group (n=101) Placebo group (n=50) Overall (n=151)
Age in years 9 (5214) 9 (5214) 9 (5214)
Number of males (%) 54 (53) 27 (54) 81 (54)
Weight in kilograms 28 (17253) 26.5 (17266) 27 (17266)
Height in cm 132 (972165) 130.50 (1002165) 132 (972165)
Oral temperature in uC 36.80 (36.1237.5) 36.75 (35.1237.4) 36.80 (35.1237.5)
Haemoglobin, g/dl* 13.3 (10.5215.3) 13.4 (10.9215.5) 13.3 (10.5215.5)
White cell count, 10
9/L‘ 7.2 (5218.2) 8.0 (4.9210.7) 7.4 (4.9218.2)
Lymphocytes, % ‘ 39.6 (14.9255.5) 39.9 (21.4267.4) 39.7 (14.9267.4)
Neutrophils, % ‘ 48.6 (29.2270) 50.5 (19.5273.8) 49.9 (19.5273.8)
Monocytes, % ‘ 5.3 (2.3212.3) 5.0 (1.4213.2) 5.2 (1.4213.2)
Basophiles, % ‘ 0.3 (020.7) 0.3 (020.7) 0.3 (020.7)
Eosinophiles, % ‘ 4.0 (0.1218.4) 3.0 (0.4215.2) 3.8 (0.1218.4)
Platelet count, 10
9/L
& 295 (1902503) 311 (1902467) 300 (1902503)
Serum Aspartate Aminotransferase AST, U/L 27 (14252) 26 (14251) 27 (14252)
Serum Alanine Aminotransferase ALT, U/L 16 (6258) 17 (5243) 16 (5258)
Creatinine, mM/L 0.47 (0.3320.70) 0.47 (0.2720.73) 0.47 (0.2720.73)
Stool culture positive for Salmonella species 75 1 2
All data are presented as median (range) unless otherwise specified.
Data from one*, two‘ and seven
& subjects not available.
doi:10.1371/journal.pone.0011778.t001
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shedding on day 4 after vaccination or later.
The presence of S. Typhi was detected in the stools of 1 (2%;
95%CI, 0–11%) of 50 subjects in the placebo group. This
occurred on day 2 and was detected using the enriched method.
No fever or adverse events were recorded for this subject. The
finding of a positive stool culture for S. Typhi in a placebo subject
was only available after unblinding of the trial. All previous and all
sequential stool cultures up to day 14 of this subject were negative.
This isolate was identified as the vaccine strain S. Typhi (Ty2
aroC
2 ssaV
2) ZH9 by subsequent PCR analysis.
Seven (7%) of 101 M01ZH09 recipients and 3 (6%) of 50
placebo recipients were detected to have a positive stool culture for
non-typhoid Salmonella between day 1 and 14 after vaccination.
Immunogenicity Outcomes. Ninety-eight (97%; 95%CI,
92–99%) of 101 subjects in the M01ZH09 group and 8 (16.0%;
95%CI, 7–29%) of 50 subjects in the placebo group developed a
positive immune response in either the S. Typhi LPS specific
Table 2. Incidence of adverse events after vaccination during 28 days of follow up (Intention to Treat population).
Event M01ZH09 (n=101) Placebo (n=50)
Number of subjects Percent (95% CI) Number of subjects Percent (95% CI)
Any adverse event 26 26 (18235) 11 22 (12236)
Gastrointestinal disorders (%) 12 12 (6220) 1 2 (0211)
related to vaccine 33 00
Abdominal pain (%) 8 8 0 0
related to vaccine 22 00
Constipation (%) 2 2 0 0
Diarrhoea 5 5 1 2
related to vaccine 33 00
Nausea 3 3 0 0
related to vaccine 11 00
Vomiting 3 3 0 0
General disorders and administration site conditions 9 9 (4216) 5 10 (3222)
Chills 1 1 1 2
Fatigue 0 0 2 4
Pyrexia 8 8 3 6
related to vaccine and severe* 11 00
Infections and infestations 1 1 (025) 0 0 (027)
Viral infection 1 1 0 0
Investigations 4 4 (1210) 0 0 (027)
Urine colour abnormal 2 2 0 0
White blood cell count increased 2 2 0 0
Metabolism and nutrition disorders 3 3 (128) 0 0 (027)
Anorexia 1 1 0 0
related to vaccine 11 00
Decreased appetite 2 2 0 0
Nervous system disorders 9 9 (4216) 1 2 (0211)
Headache 9 9 1 2
related to vaccine 22 00
Respiratory, thoracic and mediastinal disorders 6 6 (2212) 7 14 (6227)
Cough 6 6 7 14
Rhinorrhoea 1 1 0 0
Skin and subcutaneous tissue disorders 1 1 (025) 1 2 (0211)
Rash 1 1 1 2
Vascular disorders 1 1 (025) 0 0 (027)
Hypertension 1 1 0 0
Per-subject analysis of adverse events (unlikely, possibly and probably related to the vaccine) reported during 28 days of follow up. Subjects could experience more
than one adverse event. Each adverse event was only counted once for each subject and system class. There were 56 adverse events in the M01ZH09 group and 16 in
the placebo group, when repeated occurrences of a particular event in the same patient were only counted once. Adverse events that were possibly or probably related
to the vaccine are presented in italic.
*One severe adverse event was reported.
doi:10.1371/journal.pone.0011778.t002
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(Table 3). The difference in proportions of responders between the
vaccine group and the placebo group was 81.0% (95% CI; 68–
89%), the lower limit of the 95% CI of this difference was greater
than 50% and fulfilled the a priori defined criterion for an
acceptable immune response.
Median baseline LPS specific antibody levels were comparable
in both groups (Figure 2). In the M01ZH09 group, median IgA
antibody levels increased from 3 (IQR; 3–7.2) units/ml at baseline
to 94 (IQR; 19.8–231.5) units/ml and 103 (IQR; 23.9–253.5)
units/ml on days 7 and 14 respectively. On day 7, the 88 immune
responders in the vaccine group (Table 3) displayed a median 16.4
(IQR 3.75–60.25) fold rise in serum IgA antibodies relative to
baseline (Table 4, Supplements).
In the vaccine group, median LPS specific IgG antibody levels
were 66650 (IQR; 31075–123900) units/ml and 55700 (IQR;
25450–106800) units/ml on day 14 and 28, respectively,
compared to median baseline levels of 6300 (IQR 3620–16560)
units/ml. On day 14, the 91 immune responders in the M01ZH09
group (Table 3) showed a median 8.18 (IQR; 3.57–20.68) fold
increase in serum IgG antibodies relative to baseline.
Forty-two out of 44 eligible subjects provided samples for the
ELISPOT assay on day 7. All baseline ELISPOT samples were
negative (defined as ,4 ASC per 10
6 PBMC). On day 7, 28
(100%) of 28 M01ZH09 subjects who provided samples showed a
positive ELISPOT response compared to none (0%) of the 14
evaluable subjects in the placebo group. Sixteen (57%) of 28
M01ZH09 recipients displayed results of .100 spots per 10
6
PBMC and among the remaining 12 vaccine subjects numbers of
spots ranged from 8 to 128 per 10
6 PBMC. The median number
of spots in the M01ZH09 recipients was .100 (IQR 46.5-.100)
spots per 10
6 PBMC, as counting stopped above 100 spots, this
was recorded as ’’ too many spots to be counted’’. All 14 placebo
recipients showed ,4 spots per 10
6 PBMC, this was recorded as
‘‘too few spots to be counted.’’
There was strong correlation between the results of the IgA
ELISA and the IgA ELISPOT assays on day 7. Twenty-eight
(100%) of 28 M01ZH09 recipients showed a positive immune
response and 14 (100%) of 14 placebo recipients showed a
negative response in both assays.
Discussion
Interpretation
This is the first evaluation of a novel oral typhoid vaccine in
school children in an endemic country. S. Typhi (Ty2 aroC
2 ssaV
2)
ZH9 (contained in M01ZH09) is characterised by two well defined
deletion mutations, one in an aromatic amino acid biosynthesis
pathway gene and one in a functional gene of the type III secretion
system encoded by SPI-2 [9]. A single dose of 5610
9 CFU of the
vaccine strain was well tolerated and had an acceptable safety
profile. There were no serious adverse events, no withdrawals due
to adverse events and none of the subjects experienced
bacteraemia.
In general, adverse events were mild. Similar proportions of
subjects, 26% (26 of 101) in the candidate vaccine group and 22%
(11 of 50) in the placebo group reported adverse events during the
28 day follow up period (p=0.691). The overall number of adverse
events tended to be higher in the M01ZH09 group, especially
those classified as gastrointestinal disorders, nervous system
disorders and investigations.
There was one severe related adverse event in this trial, a high
fever of 39.0uC which occurred on day 0 after vaccination in a
subject who had a pre-dose elevated white blood count
(18.2610
9/L) and might have suffered from an underlying
infection. One other subject vomited after drinking approximately
half of the vaccine dose, this subject was found to have a positive
stool culture for non-typhoid Salmonella on day 0.
S. Typhi was isolated from the stools of one placebo recipient on
day 2 after vaccination which was later identified as S. Typhi (Ty2
Table 3. Proportions of responders to the candidate typhoid vaccine M01ZH09 (Intention to Treat population).
M01ZH09 group n=101 Placebo group n=50
No.
Positive Immune
response, no. (%) 95% CI No.
Positive Immune
response, no. (%) 95% CI
Detected in IgA ELISA assay
Day 7 99 88 (89) 81–94 49 1 (2) 0–11
Day 14 99 92 (93) 86–97 49 1 (2) 0–11
Day 7 or day 14 99 94 (95) 89–98 49 2 (4) 1–14
Detected in IgG ELISA assay
Day 14 99 91 (92) 85–97 49 6 (12) 5–25
Day 28 101 90 (89) 81–94 50 6 (12) 5–24
Day 14 or 28 101 93 (92) 85–97 50 8 (16) 7–29
Detected in either IgA or IgG ELISA assay
Day 7, 14 or 28 101 98 (97) 92–99 50 8 (16) 7–29
Detected in IgA ELISPOT*
Day 7 28 28 (100) 88–100 14 0 (0) 0–23
No., number of subjects who provided samples.
A positive immune response in the ELISA assay was defined by an increase of 50% (1.5 fold change) in LPS specific serum IgA and/or an increase of 70% (1.7 fold
change) in LPS specific serum IgG compared to baseline.
*44 subjects aged 11 years and above (29 subjects in the M01ZH09 group and 15 subjects in the placebo group) were eligible for the ELISPOT.
A positive ELISPOT result was defined as $4 IgA antibody secreting cells specific for S. Typhi LPS per 10
6 PBMCs. None of the subjects had a positive day 0 ELISPOT
result.
doi:10.1371/journal.pone.0011778.t003
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population). Box and whisker plots showing the distribution of antibodies according to time point and vaccination groups. The horizontal line
within each box represents the median, the top and bottom of each box represents the 75
th and 25
th percentiles, respectively, and the Ibar
represents the highest and lowest values within 1.5 times the interquartile range. Circles show outliers.
doi:10.1371/journal.pone.0011778.g002
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2 ssaV
2) ZH9 by PCR analysis. The previous stool cultures
and all following stool cultures of this subject up to day 14 were
negative. After a thorough check which included the randomisa-
tion codes and vaccination paperwork, the possibility that the
subject received M01ZH09 by error was excluded. The subject
also did not display any positive results in the immunogenicity
assays. It was concluded that the most likely cause for isolating S.
Typhi (Ty2 aroC
2 ssaV
2) ZH9 in the stools of a placebo recipient
was the mislabelling or mismatch of stool samples.
The candidate vaccine elicited a positive immune response in
97% (98/101) of the M01ZH09 recipients by ELISA and in 100%
(28/28) of M01ZH09 recipients who were evaluable by ELISPOT
assay. In conclusion M01ZH09 was safe and immunogenic in
Vietnamese children.
Generalisability
The observed safety and immunogenicity profile of the
candidate typhoid vaccine in children compares favourably to
that seen in Western adult volunteers. M01ZH09 has been tested
so far up to a nominal dose level of 5610
9 CFU in nine UK
volunteers [9] and 80 US volunteers [10,11]. Immunogenicity
results from previously published M01ZH09 trials used a 4 fold or
higher increase in LPS specific IgG antibody levels as definition of
a positive immune response in the endpoint titre ELISA and
seroconversion rates were 50% (8/16 subjects) [10] and 77.4%
(24/31 subjects) [11]. In this study, allowing for these different cut-
offs, the magnitude of the immune response seen in the children
was approximately 30 fold and 10 fold increase of median levels of
LPS specific IgA and IgG antibodies, respectively. Furthermore.
the median number of ASCs producing LPS specific IgA
antibodies, a measure for priming of the mucosal immune system,
was greater than 100 per 10
6 PBMC in this trial, this compares
favourably to an arithmetic mean of 118 ASC/10
6 PBMC seen in
a previous M01ZH09 trial in adults [10] and a geometric mean of
119 ASC/10
6 PBMC (producing IgA and IgG) seen in American
volunteers who received 4 doses of the licensed Ty21a typhoid
vaccine at a dose of 226610
9 CFU [15].
This is encouraging as one major concern for the development
of many oral vaccines has been their reduced immunogenicity
when tested in developing country populations compared to
Western volunteers [12,16]. For oral vaccines a brisk colonisation
of the intestine is necessary to become immunogenic, it might be
possible that drug resistant commensals, bacterial overgrowth,
enteric viruses or helminths interfere with the colonisation of the
new vaccine [17]. In this study, 51% (51/100) of vaccine recipients
shed S. Typhi (Ty2 aroC
2 ssaV
2) ZH9 in stools after vaccination,
one subject excreted the vaccine strain on day 3, but no shedding
was observed on day 4 and beyond. In Western adult volunteers
shedding of S. Typhi in stools was reported for slightly longer
durations and ranged from 1–6 days and 1–7 days in a small
number of volunteers, respectively [9,11].
Generalisation
Typhoid fever is still a major health problem in developing
countries, with high incidence [1,18] and high rates of antimicro-
bial drug resistance, especially in Asia [4,18]. The World Health
Organisation recommends the immunisations of school and
preschool children in endemic areas, especially where drug
resistant typhoid fever is prevalent as well as in epidemic situations
[5,19]. M01ZH09 is a promising novel oral one dose typhoid
vaccine and large trials are necessary to evaluate vaccine efficacy.
If protection from typhoid fever is demonstrated, M01ZH09 may
facilitate large vaccination campaigns due to its simpler logistic
and broader acceptance from children.
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